EBMT 2022 | An update on alloHSCT in SCD
Erfan Nur, MD, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands, comments on the current status of allogeneic hematopoietic stem cell transplantation (alloHSCT) in sickle cell disease (SCD). Although matched sibling donor transplantation (MSDT) with myeloablative conditioning (MAC) regimens has shown excellent results in children, the high toxicity of MAC means that this strategy cannot be used in adults with SCD who have accumulated vital organ damage. In recent years, advances in non-MAC regimens and improvements in supportive care have led to lower rates of graft failure in adult patients and have allowed patients to undergo haploidentical SCT with acceptable toxicity rates. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Disclosures
Novartis: consultancy, ad board, research funding, speakers bureau; Roche: speakers bureau; Celgene: speakers bureau
